NASDAQ, IRIX - Iridex Corp
semiconductor-based laser systems used to treat eye diseases in ophthalmology
and skin conditions in dermatology (also referred to as aesthetics). Our
products are sold in the United States predominantly through a direct sales
force and internationally through 68 independent distributors into 107
countries. Total product sales in 2004, 2003 and 2002 were $32.8 million,
$31.7 million and $30.6 million respectively, which generated a net income
(loss) for those corresponding years of ($402,000), $371,000 and $150,000. The
net loss for 2004 of ($402,000) included a one-time $1.0 million charge to
establish a reserve for sales taxes and interest, which the Company chose not to
retroactively collect from our customers.
Our ophthalmology products are used in the treatment of serious eye
diseases, including the three leading causes of irreversible blindness,
age-related macular degeneration (AMD), diabetic retinopathy and glaucoma. ...
Read SEC Filing on NASDAQ.com »